Use of IL-1β antibody in the treatment or prevention of myelodysplastic syndrome

摘要

The present disclosure relates to the use of IL-1β binding antibodies, especially canakinumab and gebokizumab, and biomarkers for the treatment and / or prevention of cancer associated with myelodysplastic syndrome (MDS).